Investigational New Drugs logo Springer logo

Publisher: Springer

Related content
Volume 16, Number 3, 1998

all issues

Cryptophycin 1 cellular levels and effects in vitro using L1210 cells
pp. 199-204(6)
Authors: Foster, B.J.; Fortuna, M.; Media, J.; Wiegand, R.A.; Valeriote, F.A.

The folate receptor as a potential therapeutic anticancer target
pp. 205-219(15)
Authors: Gruner, B.A.; Weitman, S.D.; Weitman, S.D.

Effects of SW 33377, SW 68210 and SW 71425 thioxanthones on in vitro colony formation of freshly explanted human tumor cells
pp. 221-225(5)
Authors: Izbicka, E.; Lawrence, R.; Davidson, K.; Rake, J.B.; von Hoff, D.D.

Compatibility and stability of bryostatin 1 in infusion devices
pp. 227-236(10)
Authors: Cheung, A.P.; Hallock, Y.F.; Vishnuvajjala, B.R.; Nguyenle, T.; Wang, E.

Phase I study of paclitaxel administered by ten-day continuous infusion
pp. 237-243(7)
Authors: Shade, R.J.; Pisters, K.M.W.; Huber, M.H.; Fossella, F.; Perez-Soler, R.; Shin, D.M.; Kurie, J.; Glisson, B.; Lippman, S.; Lee, J.S.

Phase I and pharmacologic study of oral (E)-2′-deoxy-2′-(fluoromethylene) cytidine: on a daily × 5-day schedule
pp. 245-254(10)
Authors: Masuda, N.; Negoro, S.; Takeda, K.; Takifuji, N.; Hirashima, T.; Yana, T.; Kurata, N.; Kuwabara, T.; Kobayashi, S.; Kudoh, S.; Matsui, K.; Takada, M.; Fukuoka, M.

Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer
pp. 255-258(4)
Authors: Rajagopalan, K.; Peereboom, D.; Peereboom, D.; Budd, G.T.; Budd, G.T.; Olencki, T.; Olencki, T.; Murthy, S.; Elson, P.; McLain, D.; Bukowski, R.; Bukowski, R.

Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer: the Canadian experience
pp. 265-270(6)
Authors: Latreille, J.; Gelmon, K.A.; Hirsh, V.; Laberge, F.; Maksymiuk, A.W.; Shepherd, F.A.; Delorme, F.; Bérille, J.

Evaluation of Tomudex in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group study
pp. 271-274(4)
Authors: Samlowski, W.E.; Lew, D.; Kuebler, P.J.; Kolodziej, M.A.; Medina, J.E.; Mangan, K.F.; Moore Jr, D.F.; Schuller, D.E.; Ensley, J.F.

Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer
pp. 275-278(4)
Authors: Mani, S.; Mani, S.; Kugler, J.W.; Knost, J.A.; Sciortino, D.F.; Gibbons, J.; Garcia, J.C.; Ansari, R.H.; Schilsky, R.L.; Schilsky, R.L.; Schilsky, R.L.; Vokes, E.E.; Vokes, E.E.; Vokes, E.E.

Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced hepatocellular carcinoma
pp. 279-283(5)
Authors: Mani, S.; Mani, S.; Schiano, T.; Garcia, J.C.; Ansari, R.H.; Samuels, B.; Sciortino, D.F.; Tembe, S.; Shulman, K.L.; Baker, A.; Benner, S.E.; Vokes, E.E.; Vokes, E.E.

Instructions for authors
pp. 285-286(2)

all issues

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page